BIRC6 as a diagnostic and therapeutic target for triple-negative breast cancer

By detecting and reducing the expression level of BIRC6 protein, specific antibodies and gene editing technology are used to solve the problem of insensitive chemotherapy for triple-negative breast cancer, the diagnosis and treatment of triple-negative breast cancer is achieved, and the survival prognosis of patients is improved.

CN113702635BInactive Publication Date: 2024-11-26SHENZHEN LUOHU PEOPLELS HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110835658.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-07-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

No effective targeted therapeutic methods have been found in the prior art to deal with triple-negative breast cancer, especially BIRC6, in triple-negative breast cancer, resulting in as high as 60%-70% of patients who are insensitive to chemotherapy.

Method used

By detecting and reducing the expression level of BIRC6 protein, using specific antibodies, siRNA, shRNA, CRISPR and other technologies, methods are developed for diagnosing and treating triple-negative breast cancer. The EGF-JNK pathway regulates the stability of BIRC6 protein to inhibit its expression.

Benefits of technology

Effectively used in the diagnosis and treatment of triple-negative breast cancer, reducing BIRC6 expression levels can inhibit cancer cell growth, improve patient survival prognosis, and provide new targeted therapy strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113702635B_ABST
    Figure CN113702635B_ABST
Patent Text Reader

Abstract

The present invention relates to an apoptosis inhibitor protein (BIRC6) that can be used as a diagnostic target and a therapeutic target for triple-negative breast cancer. In particular, the present invention discloses that BIRC6 is significantly overexpressed in triple-negative breast cancer cell lines and tissues, and that the overexpression can promote the proliferation of triple-negative breast cancer cells and is associated with a short prognosis and survival time of triple-negative breast cancer patients. Reducing BIRC6 expression can trigger apoptosis and lead to growth inhibition of triple-negative breast cancer cells, so inhibiting BIRC6 expression represents a new strategy for the treatment of triple-negative breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to BIRC6 as a target for diagnosis and treatment of triple-negative breast cancer. Background Art

[0002] Triple-negative breast cancer (TNBC) refers specifically to breast cancer types with loss of ER and PgR expression and overexpression or loss of HER2 gene amplification, accounting for 12%-17% of all breast cancers. Compared with other subtypes, TNBC is more biologically aggressive, with a higher rate of early distant recurrence and a worse 5-year prognosis. Although PARP inhibitors and PD-L1 antibodies atezolizumab have been approved for use in TNBC patients with BRCA mutations and positive PD-L1 expression, targeted therapy for TNBC is still in its early stages, and chemotherapy remains the standard treatment. Although TNBC patients have a certain response rate to chemotherapy, 60%-70% of patients are still insensitive to chemotherapy. Therefore, there is an urgent need to identify more molecular targets that can be used for the treatment of TNBC and develop corresponding targeted therapeutic methods.

[0003] BIRC6, also known as Apollon or BRUCE, is a member of the inhibitor of apoptosis protein (IAP) family with a very large molecular weight (close to 530 kDa) and little research. BIRC6 contains BIR and UBC domains at its N-terminus and C-terminus, respectively, which enable it to have both ubiquitin binding activity and apoptosis inhibition activity. Due to the presence of the UBC domain, BIRC6 has the dual function of E2 / E3 ubiquitin ligase, that is, it only needs E1 to ubiquitinate downstream substrates. Studies have shown that BIRC6 causes ubiquitination and proteasomal degradation of pro-apoptotic proteins SMAC, caspase-9, HtrA2, and p53.

[0004] A large amount of evidence shows that BIRC6 is highly expressed in a variety of cancer types, including neonatal acute myeloid leukemia, prostate cancer, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and colorectal cancer. However, the expression pattern and biological function of BIRC6 in the development of triple-negative breast cancer are still unclear. More importantly, the molecular mechanism of BIRC6 overexpression in cancer is also poorly understood. Summary of the invention

[0005] In view of this, the present invention relates to an apoptosis inhibitor protein BIRC6 that can be used as a diagnostic target and therapeutic target for triple-negative breast cancer. The overexpression of BIRC6 can promote the proliferation of triple-negative breast cancer cells and is related to the short prognosis survival time of triple-negative breast cancer patients. Therefore, it can be used as a marker and diagnostic marker for triple-negative breast cancer. Reducing BIRC6 expression can trigger apoptosis and lead to growth inhibition of triple-negative breast cancer cells. Therefore, inhibiting BIRC6 expression represents a new strategy for the treatment of triple-negative breast cancer. The present invention also studies the upstream regulatory mechanism of BIRC6 and finds that the EGF-JNK pathway can increase the protein stability of BIRC6.

[0006] According to one aspect of the present invention, there is provided use of a reagent for detecting the expression level of BIRC6 protein in the preparation of a diagnostic agent or a diagnostic kit for triple-negative breast cancer.

[0007] In one embodiment, the present invention provides a method for diagnosing triple-negative breast cancer, the method comprising detecting the protein expression level of BIRC6 in a sample of a subject, wherein overexpression of BIRC6 in the sample of the subject relative to a control (healthy or non-triple-negative breast cancer sample) indicates that the subject has a (high) risk of having triple-negative breast cancer.

[0008] In one embodiment, the present invention provides a reagent for detecting the expression level of BIRC6 protein, which is used for diagnosing triple-negative breast cancer.

[0009] In one embodiment, the agent is a BIRC6-specific antibody.

[0010] In another preferred embodiment, the protein sequence of BIRC6 is shown as SEQ ID NO.1 (UniProtKB / Swiss-Prot accession number Q9NR09).

[0011] According to another aspect of the present invention, provided is the use of an agent for reducing or inhibiting BIRC6 expression in the preparation of a drug for treating triple-negative breast cancer.

[0012] In one embodiment, the present invention provides an agent for reducing or inhibiting the expression of BIRC6 for use as a medicament, in particular as a medicament for treating triple-negative breast cancer.

[0013] In another embodiment, the present invention provides a method for treating triple-negative breast cancer, comprising administering to a subject in need thereof an effective amount of an agent that reduces or inhibits BIRC6 expression.

[0014] The nature of the agent that reduces or inhibits the expression of BIRC6 is not critical to the invention, provided that it reduces or inhibits the expression of BIRC6.

[0015] According to a preferred experimental scheme, the agent that reduces or inhibits BIRC6 expression is selected from the group consisting of: gapmer, antisense RNA, siRNA, esiRNA, shRNA, miRNA, RNA aptamer, TALEN, CRISPR and zinc finger nuclease. In a particularly preferred embodiment, the specific sequences used for shRNA and CRISPR are those used in the examples of the present application specification.

[0016] According to a preferred experimental scheme, the nucleotide sequence of BIRC6 is shown as SEQ ID NO.2 (Ensembl accession number ENSG00000115760).

[0017] In another embodiment, the medicament further comprises another anticancer agent such as a chemotherapeutic agent, such as an agent for reducing or inhibiting the expression of BIRC6 or an agent for inhibiting the binding of BIRC6 to JNK. Or the medicament is used in combination with a method for reducing or inhibiting the expression of BIRC6 or a method for inhibiting the binding of BIRC6 to JNK. Even if the inhibition of BIRC6 is sufficient to achieve the effect of treating triple-negative breast cancer, it is expected that when the agent for reducing or inhibiting the expression of BIRC6 is combined with other anticancer drugs such as chemotherapeutic agents, a stronger or even synergistic anticancer effect can be obtained.

[0018] According to another aspect of the present invention, a method for screening candidate drugs for treating triple-negative breast cancer is provided, the method comprising the following steps:

[0019] 1) Determine the expression level of BIRC6 in cancer cells overexpressing BIRC6;

[0020] 2) contacting the candidate compound with the cancer cells identified in step 1);

[0021] 3) determining the expression level of BIRC6 in the cancer cells obtained in step 2);

[0022] 4) comparing the expression levels of BIRC6 determined in step 1) and step 3), wherein a decrease in the expression level of BIRC6 indicates that the candidate compound has anti-cancer potential.

[0023] Compared with the prior art, the present invention confirms for the first time the existence of a new agent that can reduce or simulate the expression of BIRC6, and by detecting the gene expression of triple-negative breast cancer patients using this agent, it is found that this agent can significantly reduce the expression of BIRC6, thereby providing new ideas for accurate diagnosis of tumors, and also laying a solid foundation for reducing the recurrence rate of triple-negative breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The above features and characteristics of the present invention will become more apparent from the following detailed description in conjunction with the accompanying drawings, in which:

[0025] Figure 1 The results shown in A to D show that BIRC6 is highly expressed in triple-negative breast cancer cell lines and tissues; among them:

[0026] Figure 1 A shows the detection of BIRC6 protein expression levels in cell lines by immunoblotting and quantitative analysis;

[0027] Figure 1 B shows a typical immunohistochemical staining case of BIRC6 in tumor samples of triple-negative breast cancer patients. Case J07A2470 represents a BIRC6-positive patient, and case J07A2313 represents a BIRC6-negative patient;

[0028] Figure 1 C is the expression of BIRC6 in 90 triple-negative breast cancer tumor samples;

[0029] Figure 1 D is the Kaplan-Meier survival curve of triple-negative breast cancer patients based on BIRC6 expression;

[0030] Figure 2 BIRC6 promotes the occurrence of triple-negative breast cancer, including:

[0031] Figure 2 A shows that three different shRNAs have good knockdown efficiency for BIRC6 in MDA-MB-468 and Hs578T cells;

[0032] Figure 2 B shows the cell proliferation rate detected by MTT assay;

[0033] Figure 2 C shows the clone formation ability of cells detected by clone formation experiment;

[0034] Figure 2 D shows CRISPR-Cas9 knockout of BIRC6 in Hs578T cells and re-expression of a plasmid encoding the BIRC6 coding region in BIRC6 knockout cell clones;

[0035] Figure 2 E shows the cell proliferation rate detected by MTT assay;

[0036] Figure 2 F shows the clone formation ability of cells detected by clone formation experiment;

[0037] Figure 2G shows the cell apoptosis detected by flow cytometry;

[0038] Figure 2 H shows the tumor growth curves of subcutaneous xenografts of MDA-MB-468 and Hs578T cells;

[0039] Figure 2 I shows the expression level of apoptosis marker (cleaved CASP3) in tumor tissues detected by immunohistochemistry;

[0040] Figure 3 The results shown in show that the EGF-JNK pathway can regulate the protein stability of BIRC6, including:

[0041] Figure 3 A shows that MDA-MB-468 and Hs578T cells were serum starved for 48 h and then stimulated with EGF for 30 min, and then the protein expression of BIRC6 was detected by immunoblotting;

[0042] Figure 3 B shows that Hs578T cells were treated with JNK inhibitor SP600125 for 1.5 h and then stimulated with EGF for 30 min; the protein expression of BIRC6 was then detected by immunoblotting;

[0043] Figure 3 C shows the interaction between BIRC6 and JNK detected by co-immunoprecipitation experiment;

[0044] Figure 3 D shows that Hs578T cells were treated with EGF and then treated with MG132 (10 μM) for 6 h, followed by immunoprecipitation to detect the ubiquitination level of BIRC6;

[0045] Figure 3 E shows that Hs578T cells were treated with SP600125 and then treated with cyclohexylamine (CHX, 100 μg / ml) for the indicated time, and then the protein expression of BIRC6 was detected by immunoblotting;

[0046] Figure 3 F shows that Hs578T cells were treated with EGF and then with CHX for the indicated time, and then the protein expression of BIRC6 was detected by immunoblotting. DETAILED DESCRIPTION

[0047] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0048] The BIRC6 described in the present invention is a protein coding gene, whose protein sequence can be represented by SEQ ID NO:1, and whose nucleic acid sequence can be represented by SEQ ID NO:2.

[0049] The term "reducing or inhibiting BIRC6 expression" refers to reducing the expression level of BIRC6 to less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 15% or less than 10% of the original expression level, such as less than 5%, less than 2%, less than 1% or even 0%. In one embodiment, the expression of BIRC6 can be reduced or inhibited by gene knockout or knockdown.

[0050] The technology of gene knockout or knockdown is well known in the art, including but not limited to, retroviral gene transfer, causing mutations, such as point mutations, insertions, deletions, frameshifts, or missense mutations. Another way to knock out a gene is to use zinc finger nucleases. Zinc finger nucleases (ZFNs) are artificial restriction enzymes produced by fusing zinc finger DNA binding domains with DNA cleavage domains. The zinc finger domains can be modified to target the target DNA sequence, which can enable zinc finger nucleases to target unique sequences in complex genomes. Other genome customization technologies that can be used to knock out genes include TAL effector nucleases (TALENs). Another technology is the genome editing technology CRISPR / Cas9 system, which can be used to achieve RNA-guided genome modification.

[0051] The technology for achieving "reducing or inhibiting BIRC6 expression" may also include the use of gapmer, antisense RNA, siRNA, esiRNA, shRNA, miRNA or RNA aptamer.

[0052] "Antisense RNA" refers to an RNA molecule that is complementary to mRNA, and also includes RNA molecules that are complementary to other RNAs. Since ribosomes cannot translate double-stranded RNA, antisense RNA specifically binds to mRNA, i.e., inhibits the translation of the mRNA. For example, the antisense construct can be delivered as an expression plasmid, wherein when the expression plasmid is expressed in a cell, RNA is produced that is complementary to at least one unique portion of BIRC6 in the cell.

[0053] Another special form of the antisense RNA strategy is gapmer. Gapmer is a chimeric antisense oligonucleotide that contains a central block of deoxynucleotide monomers that is long enough to induce RNase H cleavage. The design and synthesis of gapmers are well known to those skilled in the art and can be performed by commercial companies.

[0054] "Small interfering RNA (siRNA)", sometimes called short interfering RNA or silencing RNA, is a type of double-stranded RNA molecule, about 20-25 base pairs in length, which acts through the RNA interference (RNAi) pathway. It interferes with the post-transcriptional degradation of mRNA expressing a specific gene with a complementary nucleotide sequence, thereby preventing translation. Techniques for selecting target sequences for siRNA are well known in the art.

[0055] "Short hairpin RNA" (shRNA) is an RNA sequence consisting of two short inverted repeats that can silence gene expression via RNA interference (RNAi).

[0056] The full English name of "esiRNA" is Endoribonuclease-prepared siRNAs, which is a mixture of siRNAs generated by cutting long double-stranded RNA (dsRNA) by RNase III (a ribonuclease) of Escherichia coli. The length is between 18-25bp and can be used to efficiently knock out the expression level of the target gene.

[0057] The present invention is based on the following discovery: BIRC6 can be used as a biomarker and therapeutic target for triple-negative breast cancer. Therefore, the present invention provides the use of a reagent for detecting the expression level of BIRC6 protein in the preparation of a diagnostic agent or a diagnostic kit for triple-negative breast cancer. The present invention also provides the use of a reagent for reducing or inhibiting the expression of BIRC6 in the preparation of a drug for treating triple-negative breast cancer.

[0058] In addition, the present invention also provides a method for screening anti-triple-negative breast cancer drugs, which includes the step of determining whether the candidate compound can reduce or inhibit the expression of BIRC6.

[0059] The present invention is further described in the following examples. These examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The chemical substances used in the following reactions are all commercially available products unless otherwise indicated.

[0060] Unpaired Student's t-test was used as statistical analysis in the present invention. Statistical calculations were performed using Microsoft Excel. When P<0.05, the P value was significant; ** indicates P<0.01.

[0061] Example 1

[0062] Example 1 of the present invention provides a study on the expression level of BIRC6 in triple-negative breast cancer cell lines and tissues

[0063] Eight triple-negative breast cancer cell lines, seven non-triple-negative breast cancer cell lines, and two normal breast epithelial tissue cell lines were selected, all of which were derived from ATCC. The above cells were lysed with RIPA lysis buffer to obtain protein supernatant, which was quantified by BCA method and mixed with loading buffer, and then separated by SDS-PAGE gel electrophoresis (separation gel concentration 6%). The protein on the gel was transferred to a PVDF membrane, which was blocked with 5% skim milk at room temperature for 1 hour, and then incubated with an antibody that recognizes BIRC6 (Abcam, ab19609) on a shaker at 4°C overnight. The next day, the membrane was washed with TBST buffer 3 times for 10 minutes each time; then, it was incubated with the corresponding HRP-labeled secondary antibody on a shaker at room temperature for 1 hour. After incubation, it was washed again with TBST buffer 3 times for 10 minutes each time; after washing, the chemiluminescent signal was detected with ECL developer and grayscale quantitative analysis was performed.

[0064] The results showed that BIRC6 expression tended to be increased in TNBC cell lines compared with normal breast epithelial cell lines and non-TNBC cell lines (e.g. Figure 1 A).

[0065] Furthermore, a tissue microarray (Shanghai Xinchao) containing 90 triple-negative breast cancer tumor tissue samples was selected. The tissue microarray was incubated with a primary antibody recognizing BIRC6 (Abcam, ab19609), followed by a biotin-conjugated secondary antibody and streptavidin-HRP; the immune reaction signal was detected by DAB, and the slide was imaged after hematoxylin counterstaining.

[0066] The results showed that BIRC6 was highly expressed in tumor samples of TNBC patients, with a proportion as high as 66 / 90 cases (73.3%, Figure 1 BC).

[0067] In addition, the analysis results of the KM-plotter database showed that the recurrence-free survival rate of triple-negative breast cancer patients with high BIRC6 expression was significantly worse than that of patients with low BIRC6 expression (P = 0.0074, Figure 1 D).

[0068] Example 2

[0069] Example 2 of the present invention provides a cell-level study of BIRC6

[0070] Two TNBC cell lines, Hs578T and MDA-MB-468, were selected, and virus-packaged shRNA was used to construct a BIRC6 knockdown stable cell line (the shRNA sequence is shown below).

[0071] First, the virus was packaged. 293T cells (ATCC) were inoculated in 100mm dishes. The next day, transfection was performed. The third-generation lentiviral packaging vector pMDLg / pRRE, pRSV-Rev and pMD2.G (mixed in equal molar ratio, total 9μg) and shRNA expression vector (total 9μg) were added to sterile water, and 61μl 2M CaCl2 was added to make the total volume of the three reach 500μl, and mixed; an equal volume of 2×HBS salt solution was added dropwise, and the tube wall was flicked at the same time to mix each drop in time after addition; after standing for 2min, the 1ml calcium phosphate-DNA suspension was immediately added dropwise to the cell culture medium of the above monolayer cells, and the dish was gently shaken to mix. After 8h, the culture medium and DNA precipitate were aspirated, and the supernatant containing the virus was collected after 24h and 48h, and the virus was concentrated by PEG8000.

[0072] The specific steps are as follows: First, the virus supernatant is centrifuged twice at 4°C and 2000pm for 5 minutes to remove cells and other debris, and then filtered through a 0.45μm filter membrane with low protein adsorption; secondly, 50% PEG8000 is added to the filtered supernatant to a final concentration of 10%, and then 5M NaC1 is added to a final concentration of 0.15M after mixing, and then it is incubated at 4°C overnight; finally, centrifuged at 4°C and 2000g for 10 minutes to obtain a concentrated virus precipitate, and the virus precipitate is resuspended in culture medium and then aliquoted and placed at -80°C for use. For the construction of a BIRC6 knockdown stable screening cell line, the cells are first inoculated in a 100mm culture dish. The next day, the virus solution and 10μl polybrene (10mg / ml) are added to 10ml culture medium. After 48 hours, puromycin is added to screen and remove cells that do not express the virus. Puromycin is added once every three days to obtain the desired stable cell line. The BIRC6 knockdown level was detected by immunoblotting. The knockdown situation is shown in Figure 2 A.

[0073] The results showed that BIRC6 knockdown could significantly inhibit cell proliferation and colony formation (such as Figure 2 BC), and BIRC6 knockdown can significantly trigger cell apoptosis (as shown in Figure 2 G).

[0074]

[0075]

[0076] In addition, we also knocked out BIRC6 using CRISPR-Cas9 technology. Plasmids expressing Cas9, sgRNA, and puromycin were transiently transfected into Hs578T cells using liposome Lipofectamine3000. After transfection, puromycin was added for selection for 3 days to remove cells that did not express the plasmid, and the single cell suspension was inoculated into a 96-well plate at a density of 0.5 cells / 100μl (the culture medium did not contain puromycin); Western blot analysis screened out BIRC6 knockout cell clones (such as Figure 2 D), and was further confirmed by sequencing.

[0077] The results showed that, similar to BIRC6 knockdown, BIRC6 knockout could also significantly inhibit cell proliferation and clone formation.

[0078] sgBIRC6 Sense 5'-3'GGGACCATCAAAGTCATCGA(SEQ ID NO:11)

[0079] sgCtrl Antisense 5'-3'GGGCGAGGAGCTGTTCACCG(SEQ ID NO:12)

[0080] Furthermore, we used lipofectamine3000 to transfect the plasmid pcDNA3-myc-BIRC6 expressing the BIRC6 coding region and neomycin into the above BIRC6 knockout cells. After transfection, G418 was added to screen and remove cells that did not express the plasmid, and the single cell suspension was inoculated into a 96-well plate at a density of 0.5 cells / 100μl (the culture medium did not contain G418); Western blot analysis was performed to screen out cell clones that re-expressed BIRC6 (such as Figure 2 E).

[0081] The results showed that re-expression of BIRC6 effectively rescued the survival inhibition induced by BIRC6 knockout and promoted the proliferation and clone formation of triple-negative breast cancer cells ( Figure 2 EF).

[0082] Example 3

[0083] Example 3 of the present invention provides animal level research of BIRC6

[0084] We studied the effect of BIRC6 on the tumorigenicity of triple-negative breast cancer cells. The BIRC6-knockdown MDA-MB-468 cell line was injected subcutaneously into athymic nude mice (BALB / c nude mice, female, Shanghai Slake). Similarly, the BIRC6-knockdown Hs578T cell line was injected subcutaneously into NOD / SCID mice (female, Jicui Yaokang). When the tumor size was visible to the naked eye, the length and width of the tumor were measured with a vernier caliper every 4-5 days. The formula for calculating tumor size is: V = 0.5 × L × W 2 (V: volume, L: length, W: width).

[0085] The results showed that BIRC6 knockdown MDA-MB-468 cells could hardly form tumors, and BIRC6 knockdown Hs578T cells formed tumor masses that were significantly smaller than those in the control group (e.g. Figure 2 H), and immunohistochemistry showed that BIRC6 knockdown could trigger apoptosis in vivo (as shown in Figure 2 I).

[0086] In summary, through detailed experimental verification of multiple indicators such as cell proliferation, clone formation, and subcutaneous tumor formation, we believe that BIRC6 has a significant function in inhibiting the occurrence and development of triple-negative breast cancer and is a potential therapeutic target.

[0087] Example 4

[0088] Example 4 of the present invention provides a study on the upstream regulatory mechanism of BIRC6

[0089] Two TNBC cell lines, Hs578T and MDA-MB-468, were selected. After 48 hours of serum starvation, they were treated with EGF for 30 minutes and the protein expression of BIRC6 was detected. The results showed that EGF stimulation could upregulate the protein expression of BIRC6 in a relatively short period of time (e.g. Figure 3 A), revealing that EGF regulates BIRC6 expression after translation rather than during transcription or translation. Hs578T cells were serum starved for 48 h and then treated with the kinase JNK inhibitor SP600125 (10 μM) for 1.5 h and EGF for 30 min. Immunoblotting showed that the upregulation of JNK phosphorylation and BIRC6 protein expression was blocked after SP600125 treatment (as shown in Figure 3 B), revealing that the JNK pathway is the key pathway for EGF to regulate BIRC6 protein expression. The Hs578T cell lysate was immunoprecipitated with an antibody that recognizes BIRC6, and the results showed that JNK can bind to BIRC6 (as shown in Figure 3C). In addition, immunoprecipitation of Hs578T cell lysate treated with EGF using an antibody that recognizes BIRC6 showed that EGF treatment activated JNK and significantly reduced the ubiquitination level of BIRC6 (as shown in Figure 3 D). Subsequently, Hs578T cells were treated with SP600125 and then treated with the protein synthesis inhibitor CHX (100 μg / ml) for the indicated time. The results showed that SP600125 reduced the stability of BIRC6 protein (as shown in Figure 3 E).

[0090] Serum-starved Hs578T cells were treated with EGF and then treated with CHX (100 μg / ml) for the indicated time. The results showed that EGF activated JNK and increased the stability of BIRC6 protein (e.g. Figure 3 F). Taken together, these results suggest that the EGF-JNK signaling pathway contributes to the protein stability of BIRC6.

[0091] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims. Sequence Listing <110> Shenzhen Luohu District People's Hospital <120> BIRC6 as a diagnostic and therapeutic target for triple-negative breast cancer <130> 20210720 <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 4857 <212> PRT <213> Homo sapiens <400> 1 Met Val Thr Gly Gly Gly Ala Ala Pro Pro Gly Thr Val Thr Glu Pro 1 5 10 15 Leu Pro Ser Val Ile Val Leu Ser Ala Gly Arg Lys Met Ala Ala Ala 20 25 30 Ala Ala Ala Ala Ser Gly Pro Gly Cys Ser Ser Ala Ala Gly Ala Gly 35 40 45 Ala Ala Gly Val Ser Glu Trp Leu Val Leu Arg Asp Gly Cys Met His 50 55 60 Cys Asp Ala Asp Gly Leu His Ser Leu Ser Tyr His Pro Ala Leu Asn 65 70 75 80 Ala Ile Leu Ala Val Thr Ser Arg Gly Thr Ile Lys Val Ile Asp Gly 85 90 95 Thr Ser Gly Ala Thr Leu Gln Ala Ser Ala Leu Ser Ala Lys Pro Gly 100 105 110 Gly Gln Val Lys Cys Gln Tyr Ile Ser Ala Val Asp Lys Val Ile Phe 115 120 125 Val Asp Asp Tyr Ala Val Gly Cys Arg Lys Asp Leu Asn Gly Ile Leu 130 135 140 Leu Leu Asp Thr Ala Leu Gln Thr Pro Val Ser Lys Gln Asp Asp Val 145 150 155 160 Val Gln Leu Glu Leu Pro Val Thr Glu Ala Gln Gln Leu Leu Ser Ala 165 170 175 Cys Leu Glu Lys Val Asp Ile Ser Ser Thr Glu Gly Tyr Asp Leu Phe 180 185 190 Ile Thr Gln Leu Lys Asp Gly Leu Lys Asn Thr Ser His Glu Thr Ala 195 200 205 Ala Asn His Lys Val Ala Lys Trp Ala Thr Val Thr Phe His Leu Pro 210 215 220 His His Val Leu Lys Ser Ile Ala Ser Ala Ile Val Asn Glu Leu Lys 225 230 235 240 Lys Ile Asn Gln Asn Val Ala Ala Leu Pro Val Ala Ser Ser Val Met 245 250 255 Asp Arg Leu Ser Tyr Leu Leu Pro Ser Ala Arg Pro Glu Leu Gly Val 260 265 270 Gly Pro Gly Arg Ser Val Asp Arg Ser Leu Met Tyr Ser Glu Ala Asn 275 280 285 Arg Arg Glu Thr Phe Thr Ser Trp Pro His Val Gly Tyr Arg Trp Ala 290 295 300 Gln Pro Asp Pro Met Ala Gln Ala Gly Phe Tyr His Gln Pro Ala Ser 305 310 315 320 Ser Gly Asp Asp Arg Ala Met Cys Phe Thr Cys Ser Val Cys Leu Val 325 330 335 Cys Trp Glu Pro Thr Asp Glu Pro Trp Ser Glu His Glu Arg His Ser 340 345 350 Pro Asn Cys Pro Phe Val Lys Gly Glu His Thr Gln Asn Val Pro Leu 355 360 365 Ser Val Thr Leu Ala Thr Ser Pro Ala Gln Phe Pro Cys Thr Asp Gly 370 375 380 Thr Asp Arg Ile Ser Cys Phe Gly Ser Gly Ser Cys Pro His Phe Leu 385 390 395 400 Ala Ala Ala Thr Lys Arg Gly Lys Ile Cys Ile Trp Asp Val Ser Lys 405 410 415 Leu Met Lys Val His Leu Lys Phe Glu Ile Asn Ala Tyr Asp Pro Ala 420 425 430 Ile Val Gln Gln Leu Ile Leu Ser Gly Asp Pro Ser Ser Gly Val Asp 435 440 445 Ser Arg Arg Pro Thr Leu Ala Trp Leu Glu Asp Ser Ser Ser Cys Ser 450 455 460 Asp Ile Pro Lys Leu Glu Gly Asp Ser Asp Asp Leu Leu Glu Asp Ser 465 470 475 480 Asp Ser Glu Glu His Ser Arg Ser Asp Ser Val Thr Gly His Thr Ser 485 490 495 Gln Lys Glu Ala Met Glu Val Ser Leu Asp Ile Thr Ala Leu Ser Ile 500 505 510 Leu Gln Gln Pro Glu Lys Leu Gln Trp Glu Ile Val Ala Asn Val Leu 515 520 525 Glu Asp Thr Val Lys Asp Leu Glu Glu Leu Gly Ala Asn Pro Cys Leu 530 535 540 Thr Asn Ser Lys Ser Glu Lys Thr Lys Glu Lys His Gln Glu Gln His 545 550 555 560 Asn Ile Pro Phe Pro Cys Leu Leu Ala Gly Gly Leu Leu Thr Tyr Lys 565 570 575 Ser Pro Ala Thr Ser Pro Ile Ser Ser Asn Ser His Arg Ser Leu Asp 580 585 590 Gly Leu Ser Arg Thr Gln Gly Glu Ser Ile Ser Glu Gln Gly Ser Thr 595 600 605 Asp Asn Glu Ser Cys Thr Asn Ser Glu Leu Asn Ser Pro Leu Val Arg 610 615 620 Arg Thr Leu Pro Val Leu Leu Leu Tyr Ser Ile Lys Glu Ser Asp Glu 625 630 635 640 Lys Ala Gly Lys Ile Phe Ser Gln Met Asn Asn Ile Met Ser Lys Ser 645 650 655 Leu His Asp Asp Gly Phe Thr Val Pro Gln Ile Ile Glu Met Glu Leu 660 665 670 Asp Ser Gln Glu Gln Leu Leu Leu Gln Asp Pro Pro Val Thr Tyr Ile 675 680 685 Gln Gln Phe Ala Asp Ala Ala Ala Asn Leu Thr Ser Pro Asp Ser Glu 690 695 700 Lys Trp Asn Ser Val Phe Pro Lys Pro Gly Thr Leu Val Gln Cys Leu 705 710 715 720 Arg Leu Pro Lys Phe Ala Glu Glu Glu Asn Leu Cys Ile Asp Ser Ile 725 730 735 Thr Pro Cys Ala Asp Gly Ile His Leu Leu Val Gly Leu Arg Thr Cys 740 745 750 Pro Val Glu Ser Leu Ser Ala Ile Asn Gln Val Glu Ala Leu Asn Asn 755 760 765 Leu Asn Lys Leu Asn Ser Ala Leu Cys Asn Arg Arg Lys Gly Glu Leu 770 775 780 Glu Ser Asn Leu Ala Val Val Asn Gly Ala Asn Ile Ser Val Ile Gln 785 790 795 800 His Glu Ser Pro Ala Asp Val Gln Thr Pro Leu Ile Ile Gln Pro Glu 805 810 815 Gln Arg Asn Val Ser Gly Gly Tyr Leu Val Leu Tyr Lys Met Asn Tyr 820 825 830 Ala Thr Arg Ile Val Thr Leu Glu Glu Glu Pro Ile Lys Ile Gln His 835 840 845 Ile Lys Asp Pro Gln Asp Thr Ile Thr Ser Leu Ile Leu Leu Pro Pro 850 855 860 Asp Ile Leu Asp Asn Arg Glu Asp Asp Cys Glu Glu Pro Ile Glu Asp 865 870 875 880 Met Gln Leu Thr Ser Lys Asn Gly Phe Glu Arg Glu Lys Thr Ser Asp 885 890 895 Ile Ser Thr Leu Gly His Leu Val Ile Thr Thr Gln Gly Gly Tyr Val 900 905 910 Lys Ile Leu Asp Leu Ser Asn Phe Glu Ile Leu Ala Lys Val Glu Pro 915 920 925 Pro Lys Lys Glu Gly Thr Glu Glu Gln Asp Thr Phe Val Ser Val Ile 930 935 940 Tyr Cys Ser Gly Thr Asp Arg Leu Cys Ala Cys Thr Lys Gly Gly Glu 945 950 955 960 Leu His Phe Leu Gln Ile Gly Gly Thr Cys Asp Asp Ile Asp Glu Ala 965 970 975 Asp Ile Leu Val Asp Gly Ser Leu Ser Lys Gly Ile Glu Pro Ser Ser 980 985 990 Glu Gly Ser Lys Pro Leu Ser Asn Pro Ser Ser Pro Gly Ile Ser Gly 995 1000 1005 Val Asp Leu Leu Val Asp Gln Pro Phe Thr Leu Glu Ile Leu Thr Ser 1010 1015 1020 Leu Val Glu Leu Thr Arg Phe Glu Thr Leu Thr Pro Arg Phe Ser Ala 1025 1030 1035 1040 Thr Val Pro Pro Cys Trp Val Glu Val Gln Gln Glu Gln Gln Gln Arg 1045 1050 1055 Arg His Pro Gln His Leu His Gln Gln His His Gly Asp Ala Ala Gln 1060 1065 1070 His Thr Arg Thr Trp Lys Leu Gln Thr Asp Ser Asn Ser Trp Asp Glu 1075 1080 1085 His Val Phe Glu Leu Val Leu Pro Lys Ala Cys Met Val Gly His Val 1090 1095 1100 Asp Phe Lys Phe Val Leu Asn Ser Asn Ile Thr Asn Ile Pro Gln Ile 1105 1110 1115 1120 Gln Val Thr Leu Leu Lys Asn Lys Ala Pro Gly Leu Gly Lys Val Asn 1125 1130 1135 Ala Leu Asn Ile Glu Val Glu Gln Asn Gly Lys Pro Ser Leu Val Asp 1140 1145 1150 Leu Asn Glu Glu Met Gln His Met Asp Val Glu Glu Ser Gln Cys Leu 1155 1160 1165 Arg Leu Cys Pro Phe Leu Glu Asp His Lys Glu Asp Ile Leu Cys Gly 1170 1175 1180 Pro Val Trp Leu Ala Ser Gly Leu Asp Leu Ser Gly His Ala Gly Met 1185 1190 1195 1200 Leu Thr Leu Thr Ser Pro Lys Leu Val Lys Gly Met Ala Gly Gly Lys 1205 1210 1215 Tyr Arg Ser Phe Leu Ile His Val Lys Ala Val Asn Glu Arg Gly Thr 1220 1225 1230 Glu Glu Ile Cys Asn Gly Gly Met Arg Pro Val Val Arg Leu Pro Ser 1235 1240 1245 Leu Lys His Gln Ser Asn Lys Gly Tyr Ser Leu Ala Ser Leu Leu Ala 1250 1255 1260 Lys Val Ala Ala Gly Lys Glu Lys Ser Ser Asn Val Lys Asn Glu Asn 1265 1270 1275 1280 Thr Ser Gly Thr Arg Lys Ser Glu Asn Leu Arg Gly Cys Asp Leu Leu 1285 1290 1295 Gln Glu Val Ser Val Thr Ile Arg Arg Phe Lys Lys Thr Ser Ile Ser 1300 1305 1310 Lys Glu Arg Val Gln Arg Cys Ala Met Leu Gln Phe Ser Glu Phe His 1315 1320 1325 Glu Lys Leu Val Asn Thr Leu Cys Arg Lys Thr Asp Asp Gly Gln Ile 1330 1335 1340 Thr Glu His Ala Gln Ser Leu Val Leu Asp Thr Leu Cys Trp Leu Ala 1345 1350 1355 1360 Gly Val His Ser Asn Gly Pro Gly Ser Ser Lys Glu Gly Asn Glu Asn 1365 1370 1375 Leu Leu Ser Lys Thr Arg Lys Phe Leu Ser Asp Ile Val Arg Val Cys 1380 1385 1390 Phe Phe Glu Ala Gly Arg Ser Ile Ala His Lys Cys Ala Arg Phe Leu 1395 1400 1405 Ala Leu Cys Ile Ser Asn Gly Lys Cys Asp Pro Cys Gln Pro Ala Phe 1410 1415 1420 Gly Pro Val Leu Leu Lys Ala Leu Leu Asp Asn Met Ser Phe Leu Pro 1425 1430 1435 1440 Ala Ala Thr Thr Gly Gly Ser Val Tyr Trp Tyr Phe Val Leu Leu Asn 1445 1450 1455 Tyr Val Lys Asp Glu Asp Leu Ala Gly Cys Ser Thr Ala Cys Ala Ser 1460 1465 1470 Leu Leu Thr Ala Val Ser Arg Gln Leu Gln Asp Arg Leu Thr Pro Met 1475 1480 1485 Glu Ala Leu Leu Gln Thr Arg Tyr Gly Leu Tyr Ser Ser Pro Phe Asp 1490 1495 1500 Pro Val Leu Phe Asp Leu Glu Met Ser Gly Ser Ser Cys Lys Asn Val 1505 1510 1515 1520 Tyr Asn Ser Ser Ile Gly Val Gln Ser Asp Glu Ile Asp Leu Ser Asp 1525 1530 1535 Val Leu Ser Gly Asn Gly Lys Val Ser Ser Cys Thr Ala Ala Glu Gly 1540 1545 1550 Ser Phe Thr Ser Leu Thr Gly Leu Leu Glu Val Glu Pro Leu His Phe 1555 1560 1565 Thr Cys Val Ser Thr Ser Asp Gly Thr Arg Ile Glu Arg Asp Asp Ala 1570 1575 1580 Met Ser Ser Phe Gly Val Thr Pro Ala Val Gly Gly Leu Ser Ser Gly 1585 1590 1595 1600 Thr Val Gly Glu Ala Ser Thr Ala Leu Ser Ser Ala Ala Gln Val Ala 1605 1610 1615 Leu Gln Ser Leu Ser His Ala Met Ala Ser Ala Glu Gln Gln Leu Gln 1620 1625 1630 Val Leu Gln Glu Lys Gln Gln Gln Leu Leu Lys Leu Gln Gln Gln Lys 1635 1640 1645 Ala Lys Leu Glu Ala Lys Leu His Gln Thr Thr Ala Ala Ala Ala Ala 1650 1655 1660 Ala Ala Ser Ala Val Gly Pro Val His Asn Ser Val Pro Ser Asn Pro 1665 1670 1675 1680 Val Ala Ala Pro Gly Phe Phe Ile His Pro Ser Asp Val Ile Pro Pro 1685 1690 1695 Thr Pro Lys Thr Thr Pro Leu Phe Met Thr Pro Pro Leu Thr Pro Pro 1700 1705 1710 Asn Glu Ala Val Ser Val Val Ile Asn Ala Glu Leu Ala Gln Leu Phe 1715 1720 1725 Pro Gly Ser Val Ile Asp Pro Pro Ala Val Asn Leu Ala Ala His Asn 1730 1735 1740 Lys Asn Ser Asn Lys Ser Arg Met Asn Pro Leu Gly Ser Gly Leu Ala 1745 1750 1755 1760 Leu Ala Ile Ser His Ala Ser His Phe Leu Gln Pro Pro Pro His Gln 1765 1770 1775 Ser Ile Ile Ile Glu Arg Met His Ser Gly Ala Arg Arg Phe Val Thr 1780 1785 1790 Leu Asp Phe Gly Arg Pro Ile Leu Leu Thr Asp Val Leu Ile Pro Thr 1795 1800 1805 Cys Gly Asp Leu Ala Ser Leu Ser Ile Asp Ile Trp Thr Leu Gly Glu 1810 1815 1820 Glu Val Asp Gly Arg Arg Leu Val Val Ala Thr Asp Ile Ser Thr His 1825 1830 1835 1840 Ser Leu Ile Leu His Asp Leu Ile Pro Pro Pro Val Cys Arg Phe Met 1845 1850 1855 Lys Ile Thr Val Ile Gly Arg Tyr Gly Ser Thr Asn Ala Arg Ala Lys 1860 1865 1870 Ile Pro Leu Gly Phe Tyr Tyr Gly His Thr Tyr Ile Leu Pro Trp Glu 1875 1880 1885 Ser Glu Leu Lys Leu Met His Asp Pro Leu Lys Gly Glu Gly Glu Ser 1890 1895 1900 Ala Asn Gln Pro Glu Ile Asp Gln His Leu Ala Met Met Val Ala Leu 1905 1910 1915 1920 Gln Glu Asp Ile Gln Cys Arg Tyr Asn Leu Ala Cys His Arg Leu Glu 1925 1930 1935 Thr Leu Leu Gln Ser Ile Asp Leu Pro Pro Leu Asn Ser Ala Asn Asn 1940 1945 1950 Ala Gln Tyr Phe Leu Arg Lys Pro Asp Lys Ala Val Glu Glu Asp Ser 1955 1960 1965 Arg Val Phe Ser Ala Tyr Gln Asp Cys Ile Gln Leu Gln Leu Gln Leu 1970 1975 1980 Asn Leu Ala His Asn Ala Val Gln Arg Leu Lys Val Ala Leu Gly Ala 1985 1990 1995 2000 Ser Arg Lys Met Leu Ser Glu Thr Ser Asn Pro Glu Asp Leu Ile Gln 2005 2010 2015 Thr Ser Ser Thr Glu Gln Leu Arg Thr Ile Ile Arg Tyr Leu Leu Asp 2020 2025 2030 Thr Leu Leu Ser Leu Leu His Ala Ser Asn Gly His Ser Val Pro Ala 2035 2040 2045 Val Leu Gln Ser Thr Phe His Ala Gln Ala Cys Glu Glu Leu Phe Lys 2050 2055 2060 His Leu Cys Ile Ser Gly Thr Pro Lys Ile Arg Leu His Thr Gly Leu 2065 2070 2075 2080 Leu Leu Val Gln Leu Cys Gly Gly Glu Arg Trp Trp Gly Gln Phe Leu 2085 2090 2095 Ser Asn Val Leu Gln Glu Leu Tyr Asn Ser Glu Gln Leu Leu Ile Phe 2100 2105 2110 Pro Gln Asp Arg Val Phe Met Leu Leu Ser Cys Ile Gly Gln Arg Ser 2115 2120 2125 Leu Ser Asn Ser Gly Val Leu Glu Ser Leu Leu Asn Leu Leu Asp Asn 2130 2135 2140 Leu Leu Ser Pro Leu Gln Pro Gln Leu Pro Met His Arg Arg Thr Glu 2145 2150 2155 2160 Gly Val Leu Asp Ile Pro Met Ile Ser Trp Val Val Met Leu Val Ser 2165 2170 2175 Arg Leu Leu Asp Tyr Val Ala Thr Val Glu Asp Glu Ala Ala Ala Ala Ala 2180 2185 2190 Light Light Pro Leu Asn Gly Asn Gln Trp Ser Phe Ile Asn Asn Asn Leu 2195 2200 2205 His Thr Gln Ser Leu Asn Arg Ser Ser Lys Gly Ser Ser Ser Leu Asp 2210 2215 2220 Arg Leu Tyr Ser Arg Lys Ile Arg Lys Gln Leu Val His His Lys Gln 2225 2230 2235 2240 Gln Leu Asn Leu Leu Lys Ala Lys Gln Lys Ala Leu Val Glu Gln Met 2245 2250 2255 Glu Lys Glu Lys Ile Gln Ser Asn Lys Gly Ser Ser Tyr Lys Leu Leu 2260 2265 2270 Val Glu Gln Ala Lys Leu Lys Gln Ala Thr Ser Lys His Phe Lys Asp 2275 2280 2285 Leu Ile Arg Leu Arg Arg Thr Ala Glu Trp Ser Arg Ser Asn Leu Asp 2290 2295 2300 Thr Glu Val Thr Thr Ala Lys Glu Ser Pro Glu Ile Glu Pro Leu Pro 2305 2310 2315 2320 Phe Thr Leu Ala His Glu Arg Cys Ile Ser Val Val Gln Lys Leu Val 2325 2330 2335 Leu Phe Leu Leu Ser Met Asp Phe Thr Cys His Ala Asp Leu Leu Leu 2340 2345 2350 Phe Val Cys Lys Val Leu Ala Arg Ile Ala Asn Ala Thr Arg Pro Thr 2355 2360 2365 Ile His Leu Cys Glu Ile Val Asn Glu Pro Gln Leu Glu Arg Leu Leu 2370 2375 2380 Leu Leu Leu Val Gly Thr Asp Phe Asn Arg Gly Asp Ile Ser Trp Gly 2385 2390 2395 2400 Gly Ala Trp Ala Gln Tyr Ser Leu Thr Cys Met Leu Gln Asp Ile Leu 2405 2410 2415 Ala Gly Glu Leu Leu Ala Pro Val Ala Ala Glu Ala Met Glu Glu Gly 2420 2425 2430 Thr Val Gly Asp Asp Val Gly Ala Thr Ala Gly Asp Ser Asp Asp Ser 2435 2440 2445 Leu Gln Gln Ser Ser Val Gln Leu Leu Glu Thr Ile Asp Glu Pro Leu 2450 2455 2460 Thr His Asp Ile Thr Gly Ala Pro Pro Leu Ser Ser Leu Glu Lys Asp 2465 2470 2475 2480 Lys Glu Ile Asp Leu Glu Leu Leu Gln Asp Leu Met Glu Val Asp Ile 2485 2490 2495 Asp Pro Leu Asp Ile Asp Leu Glu Lys Asp Pro Leu Ala Ala Lys Val 2500 2505 2510 Phe Lys Pro Ile Ser Ser Thr Trp Tyr Asp Tyr Trp Gly Ala Asp Tyr 2515 2520 2525 Gly Thr Tyr Asn Tyr Asn Pro Tyr Ile Gly Gly Leu Gly Ile Pro Val 2530 2535 2540 Ala Lys Pro Pro Ala Asn Thr Glu Lys Asn Gly Ser Gln Thr Val Ser 2545 2550 2555 2560 Val Ser Val Ser Gln Ala Leu Asp Ala Arg Leu Glu Val Gly Leu Glu 2565 2570 2575 Gln Gln Ala Glu Leu Met Leu Lys Met Met Ser Thr Leu Glu Ala Asp 2580 2585 2590 Ser Ile Leu Gln Ala Leu Thr Asn Thr Ser Pro Thr Leu Ser Gln Ser 2595 2600 2605 Pro Thr Gly Thr Asp Asp Ser Leu Leu Gly Gly Leu Gln Ala Ala Asn 2610 2615 2620 Gln Thr Ser Gln Leu Ile Ile Gln Leu Ser Ser Val Pro Met Leu Asn 2625 2630 2635 2640 Val Cys Phe Asn Lys Leu Phe Ser Met Leu Gln Val His His Val Gln 2645 2650 2655 Leu Glu Ser Leu Leu Gln Leu Trp Leu Thr Leu Ser Leu Asn Ser Ser 2660 2665 2670 Ser Thr Gly Asn Lys Glu Asn Gly Ala Asp Ile Phe Leu Tyr Asn Ala 2675 2680 2685 Asn Arg Ile Pro Val Ile Ser Leu Asn Gln Ala Ser Ile Thr Ser Phe 2690 2695 2700 Leu Thr Val Leu Ala Trp Tyr Pro Asn Thr Leu Leu Arg Thr Trp Cys 2705 ​​2710 2715 2720 Leu Val Leu His Ser Leu Thr Leu Met Thr Asn Met Gln Leu Asn Ser 2725 2730 2735 Gly Ser Ser Ser Ala Ile Gly Thr Gln Glu Ser Thr Ala His Leu Leu 2740 2745 2750 Val Ser Asp Pro Asn Leu Ile His Val Leu Val Lys Phe Leu Ser Gly 2755 2760 2765 Thr Ser Pro His Gly Thr Asn Gln His Ser Pro Gln Val Gly Pro Thr 2770 2775 2780 Ala Thr Gln Ala Met Gln Glu Phe Leu Thr Arg Leu Gln Val His Leu 2785 2790 2795 2800 Ser Ser Thr Cys Pro Gln Ile Phe Ser Glu Phe Leu Leu Lys Leu Ile 2805 2810 2815 His Ile Leu Ser Thr Glu Arg Gly Ala Phe Gln Thr Gly Gln Gly Pro 2820 2825 2830 Leu Asp Ala Gln Val Lys Leu Leu Glu Phe Thr Leu Glu Gln Asn Phe 2835 2840 2845 Glu Val Val Ser Val Ser Thr Ile Ser Ala Val Ile Glu Ser Val Thr 2850 2855 2860 Phe Leu Val His His Tyr Ile Thr Cys Ser Asp Lys Val Met Ser Arg 2865 2870 2875 2880 Ser Gly Ser Asp Ser Ser Val Gly Ala Arg Ala Cys Phe Gly Gly Leu 2885 2890 2895 Phe Ala Asn Leu Ile Arg Pro Gly Asp Ala Lys Ala Val Cys Gly Glu 2900 2905 2910 Met Thr Arg Asp Gln Leu Met Phe Asp Leu Leu Lys Leu Val Asn Ile 2915 2920 2925 Leu Val Gln Leu Pro Leu Ser Gly Asn Arg Glu Tyr Ser Ala Arg Val 2930 2935 2940 Ser Val Thr Thr Asn Thr Thr Asp Ser Val Ser Asp Glu Glu Lys Val 2945 2950 2955 2960 Ser Gly Gly Lys Asp Gly Asn Gly Ser Ser Thr Ser Val Gln Gly Ser 2965 2970 2975 Pro Ala Tyr Val Ala Asp Leu Val Leu Ala Asn Gln Gln Ile Met Ser 2980 2985 2990 Gln Ile Leu Ser Ala Leu Gly Leu Cys Asn Ser Ser Ala Met Ala Met 2995 3000 3005 Ile Ile Gly Ala Ser Gly Leu His Leu Thr Lys His Glu Asn Phe His 3010 3015 3020 Gly Gly Leu Asp Ala Ile Ser Val Gly Asp Gly Leu Phe Thr Ile Leu 3025 3030 3035 3040 Thr Thr Leu Ser Lys Lys Ala Ser Thr Val His Met Met Leu Gln Pro 3045 3050 3055 Ile Leu Thr Tyr Met Ala Cys Gly Tyr Met Gly Arg Gln Gly Ser Leu 3060 3065 3070 Ala Thr Cys Gln Leu Ser Glu Pro Leu Leu Trp Phe Ile Leu Arg Val 3075 3080 3085 Leu Asp Thr Ser Asp Ala Leu Lys Ala Phe His Asp Met Gly Gly Val 3090 3095 3100 Gln Leu Ile Cys Asn Asn Met Val Thr Ser Thr Arg Ala Ile Val Asn 3105 3110 3115 3120 Thr Ala Arg Ser Met Val Ser Thr Ile Met Lys Phe Leu Asp Ser Gly 3125 3130 3135 Pro Asn Lys Ala Val Asp Ser Thr Leu Lys Thr Arg Ile Leu Ala Ser 3140 3145 3150 Glu Pro Asp Asn Ala Glu Gly Ile His Asn Phe Ala Pro Leu Gly Thr 3155 3160 3165 Ile Thr Ser Ser Ser Pro Thr Ala Gln Pro Ala Glu Val Leu Leu Gln 3170 3175 3180 Ala Thr Pro Pro His Arg Arg Ala Arg Ser Ala Ala Trp Ser Tyr Ile 3185 3190 3195 3200 Phe Leu Pro Glu Glu Ala Trp Cys Asp Leu Thr Ile His Leu Pro Ala 3205 3210 3215 Ala Val Leu Leu Lys Glu Ile His Ile Gln Pro His Leu Ala Ser Leu 3220 3225 3230 Ala Thr Cys Pro Ser Ser Val Ser Val Glu Val Ser Ala Asp Gly Val 3235 3240 3245 Asn Met Leu Pro Leu Ser Thr Pro Val Val Thr Ser Gly Leu Thr Tyr 3250 3255 3260 Ile Lys Ile Gln Leu Val Lys Ala Glu Val Ala Ser Ala Val Cys Leu 3265 3270 3275 3280 Arg Leu His Arg Pro Arg Asp Ala Ser Thr Leu Gly Leu Ser Gln Ile 3285 3290 3295 Lys Leu Leu Gly Leu Thr Ala Phe Gly Thr Thr Ser Ser Ala Thr Val 3300 3305 3310 Asn Asn Pro Phe Leu Pro Ser Glu Asp Gln Val Ser Lys Thr Ser Ile 3315 3320 3325 Gly Trp Leu Arg Leu Leu His His Cys Leu Thr His Ile Ser Asp Leu 3330 3335 3340 Glu Gly Met Met Ala Ser Ala Ala Ala Pro Thr Ala Asn Leu Leu Gln 3345 3350 3355 3360 Thr Cys Ala Ala Leu Leu Met Ser Pro Tyr Cys Gly Met His Ser Pro 3365 3370 3375 Asn Ile Glu Val Val Leu Val Lys Ile Gly Leu Gln Ser Thr Arg Ile 3380 3385 3390 Gly Leu Lys Leu Ile Asp Ile Leu Leu Arg Asn Cys Ala Ala Ser Gly 3395 3400 3405 Ser Asp Pro Thr Asp Leu Asn Ser Pro Leu Leu Phe Gly Arg Leu Asn 3410 3415 3420 Gly Leu Ser Ser Asp Ser Thr Ile Asp Ile Leu Tyr Gln Leu Gly Thr 3425 3430 3435 3440 Thr Gln Asp Pro Gly Thr Lys Asp Arg Ile Gln Ala Leu Leu Lys Trp 3445 3450 3455 Val Ser Asp Ser Ala Arg Val Ala Ala Met Lys Arg Ser Gly Arg Met 3460 3465 3470 Asn Tyr Met Cys Pro Asn Ser Ser Thr Val Glu Tyr Gly Leu Leu Met 3475 3480 3485 Pro Ser Pro Ser His Leu His Cys Val Ala Ala Ile Leu Trp His Ser 3490 3495 3500 Tyr Glu Leu Leu Val Glu Tyr Asp Leu Pro Ala Leu Leu Asp Gln Glu 3505 3510 3515 3520 Leu Phe Glu Leu Leu Phe Asn Trp Ser Met Ser Leu Pro Cys Asn Met 3525 3530 3535 Val Leu Lys Lys Ala Val Asp Ser Leu Leu Cys Ser Met Cys His Val 3540 3545 3550 His Pro Asn Tyr Phe Ser Leu Leu Met Gly Trp Met Gly Ile Thr Pro 3555 3560 3565 Pro Pro Val Gln Cys His His Arg Leu Ser Met Thr Asp Asp Ser Lys 3570 3575 3580 Lys Gln Asp Leu Ser Ser Ser Leu Thr Asp Asp Ser Lys Asn Ala Gln 3585 3590 3595 3600 Ala Pro Leu Ala Leu Thr Glu Ser His Leu Ala Thr Leu Ala Ser Ser 3605 3610 3615 Ser Gln Ser Pro Glu Ala Ile Lys Gln Leu Leu Asp Ser Gly Leu Pro 3620 3625 3630 Ser Leu Leu Val Arg Ser Leu Ala Ser Phe Cys Phe Ser His Ile Ser 3635 3640 3645 Ser Ser Glu Ser Ile Ala Gln Ser Ile Asp Ile Ser Gln Asp Lys Leu 3650 3655 3660 Arg Arg His His Val Pro Gln Gln Cys Asn Lys Met Pro Ile Thr Ala 3665 3670 3675 3680 Asp Leu Val Ala Pro Ile Leu Arg Phe Leu Thr Glu Val Gly Asn Ser 3685 3690 3695 His Ile Met Lys Asp Trp Leu Gly Gly Ser Glu Val Asn Pro Leu Trp 3700 3705 3710 Thr Ala Leu Leu Phe Leu Leu Cys His Ser Gly Ser Thr Ser Gly Ser 3715 3720 3725 His Asn Leu Gly Ala Gln Gln Thr Ser Ala Arg Ser Ala Ser Leu Ser 3730 3735 3740 Ser Ala Ala Thr Thr Gly Leu Thr Thr Gln Gln Arg Thr Ala Ile Glu 3745 3750 3755 3760 Asn Ala Thr Val Ala Phe Phe Leu Gln Cys Ile Ser Cys His Pro Asn 3765 3770 3775 Asn Gln Lys Leu Met Ala Gln Val Leu Cys Glu Leu Phe Gln Thr Ser 3780 3785 3790 Pro Gln Arg Gly Asn Leu Pro Thr Ser Gly Asn Ile Ser Gly Phe Ile 3795 3800 3805 Arg Arg Leu Phe Leu Gln Leu Met Leu Glu Asp Glu Lys Val Thr Met 3810 3815 3820 Phe Leu Gln Ser Pro Cys Pro Leu Tyr Lys Gly Arg Ile Asn Ala Thr 3825 3830 3835 3840 Ser His Val Ile Gln His Pro Met Tyr Gly Ala Gly His Lys Phe Arg 3845 3850 3855 Thr Leu His Leu Pro Val Ser Thr Thr Leu Ser Asp Val Leu Asp Arg 3860 3865 3870 Val Ser Asp Thr Pro Ser Ile Thr Ala Lys Leu Ile Ser Glu Gln Lys 3875 3880 3885 Asp Asp Lys Glu Lys Lys Asn His Glu Glu Lys Glu Lys Val Lys Ala 3890 3895 3900 Glu Asn Gly Phe Gln Asp Asn Tyr Ser Val Val Val Ala Ser Gly Leu 3905 3910 3915 3920 Lys Ser Gln Ser Lys Arg Ala Val Ser Ala Thr Pro Pro Arg Pro Pro 3925 3930 3935 Ser Arg Arg Gly Arg Thr Ile Pro Asp Lys Ile Gly Ser Thr Ser Gly 3940 3945 3950 Ala Glu Ala Ala Asn Lys Ile Ile Thr Val Pro Val Phe His Leu Phe 3955 3960 3965 His Lys Leu Leu Ala Gly Gln Pro Leu Pro Ala Glu Met Thr Leu Ala 3970 3975 3980 Gln Leu Leu Thr Leu Leu Tyr Asp Arg Lys Leu Pro Gln Gly Tyr Arg 3985 3990 3995 4000 Ser Ile Asp Leu Thr Val Lys Leu Gly Ser Arg Val Ile Thr Asp Pro 4005 4010 4015 Ser Leu Ser Lys Thr Asp Ser Tyr Lys Arg Leu His Pro Glu Lys Asp 4020 4025 4030 His Gly Asp Leu Leu Ala Ser Cys Pro Glu Asp Glu Ala Leu Thr Pro 4035 4040 4045 Gly Asp Glu Cys Met Asp Gly Ile Leu Asp Glu Ser Leu Leu Glu Thr 4050 4055 4060 Cys Pro Ile Gln Ser Pro Leu Gln Val Phe Ala Gly Met Gly Gly Leu 4065 4070 4075 4080 Ala Leu Ile Ala Glu Arg Leu Pro Met Leu Tyr Pro Glu Val Ile Gln 4085 4090 4095 Gln Val Ser Ala Pro Val Val Thr Ser Thr Thr Gln Glu Lys Pro Lys 4100 4105 4110 Asp Ser Asp Gln Phe Glu Trp Val Thr Ile Glu Gln Ser Gly Glu Leu 4115 4120 4125 Val Tyr Glu Ala Pro Glu Thr Val Ala Ala Glu Pro Pro Pro Ile Lys 4130 4135 4140 Ser Ala Val Gln Thr Met Ser Pro Ile Pro Ala His Ser Leu Ala Ala 4145 4150 4155 4160 Phe Gly Leu Phe Leu Arg Leu Pro Gly Tyr Ala Glu Val Leu Leu Lys 4165 4170 4175 Glu Arg Lys His Ala Gln Cys Leu Leu Arg Leu Val Leu Gly Val Thr 4180 4185 4190 Asp Asp Gly Glu Gly Ser His Ile Leu Gln Ser Pro Ser Ala Asn Val 4195 4200 4205 Leu Pro Thr Leu Pro Phe His Val Leu Arg Ser Leu Phe Ser Thr Thr 4210 4215 4220 Pro Leu Thr Thr Asp Asp Gly Val Leu Leu Arg Arg Met Ala Leu Glu 4225 4230 4235 4240 Ile Gly Ala Leu His Leu Ile Leu Val Cys Leu Ser Ala Leu Ser His 4245 4250 4255 His Ser Pro Arg Val Pro Asn Ser Ser Val Asn Gln Thr Glu Pro Gln 4260 4265 4270 Val Ser Ser Ser His Asn Pro Thr Ser Thr Glu Glu Gln Gln Leu Tyr 4275 4280 4285 Trp Ala Lys Gly Thr Gly Phe Gly Thr Gly Ser Thr Ala Ser Gly Trp 4290 4295 4300 Asp Val Glu Gln Ala Leu Thr Lys Gln Arg Leu Glu Glu Glu His Val 4305 4310 4315 4320 Thr Cys Leu Leu Gln Val Leu Ala Ser Tyr Ile Asn Pro Val Ser Ser 4325 4330 4335 Ala Val Asn Gly Glu Ala Gln Ser Ser His Glu Thr Arg Gly Gln Asn 4340 4345 4350 Ser Asn Ala Leu Pro Ser Val Leu Leu Glu Leu Leu Ser Gln Ser Cys 4355 4360 4365 Leu Ile Pro Ala Met Ser Ser Tyr Leu Arg Asn Asp Ser Val Leu Asp 4370 4375 4380 Met Ala Arg His Val Pro Leu Tyr Arg Ala Leu Leu Glu Leu Leu Arg 4385 4390 4395 4400 Ala Ile Ala Ser Cys Ala Ala Met Val Pro Leu Leu Leu Pro Leu Ser 4405 4410 4415 Thr Glu Asn Gly Glu Glu Glu Glu Glu Gln Ser Glu Cys Gln Thr Ser 4420 4425 4430 Val Gly Thr Leu Leu Ala Lys Met Lys Thr Cys Val Asp Thr Tyr Thr 4435 4440 4445 Asn Arg Leu Arg Ser Lys Arg Glu Asn Val Lys Thr Gly Val Lys Pro 4450 4455 4460 Asp Ala Ser Asp Gln Glu Pro Glu Gly Leu Thr Leu Leu Val Pro Asp 4465 4470 4475 4480 Ile Gln Lys Thr Ala Glu Ile Val Tyr Ala Ala Thr Thr Ser Leu Arg 4485 4490 4495 Gln Ala Asn Gln Glu Lys Lys Leu Gly Glu Tyr Ser Lys Lys Ala Ala 4500 4505 4510 Met Lys Pro Lys Pro Leu Ser Val Leu Lys Ser Leu Glu Glu Lys Tyr 4515 4520 4525 Val Ala Val Met Lys Lys Leu Gln Phe Asp Thr Phe Glu Met Val Ser 4530 4535 4540 Glu Asp Glu Asp Gly Lys Leu Gly Phe Lys Val Asn Tyr His Tyr Met 4545 4550 4555 4560 Ser Gln Val Lys Asn Ala Asn Asp Ala Asn Ser Ala Ala Arg Ala Arg 4565 4570 4575 Arg Leu Ala Gln Glu Ala Val Thr Leu Ser Thr Ser Leu Pro Leu Ser 4580 4585 4590 Ser Ser Ser Ser Val Phe Val Arg Cys Asp Glu Glu Arg Leu Asp Ile 4595 4600 4605 Met Lys Val Leu Ile Thr Gly Pro Ala Asp Thr Pro Tyr Ala Asn Gly 4610 4615 4620 Cys Phe Glu Phe Asp Val Tyr Phe Pro Gln Asp Tyr Pro Ser Ser Pro 4625 4630 4635 4640 Pro Leu Val Asn Leu Glu Thr Thr Gly Gly His Ser Val Arg Phe Asn 4645 4650 4655 Pro Asn Leu Tyr Asn Asp Gly Lys Val Cys Leu Ser Ile Leu Asn Thr 4660 4665 4670 Trp His Gly Arg Pro Glu Glu Lys Trp Asn Pro Gln Thr Ser Ser Phe 4675 4680 4685 Leu Gln Val Leu Val Ser Val Gln Ser Leu Ile Leu Val Ala Glu Pro 4690 4695 4700 Tyr Phe Asn Glu Pro Gly Tyr Glu Arg Ser Arg Gly Thr Pro Ser Gly 4705 4710 4715 4720 Thr Gln Ser Ser Arg Glu Tyr Asp Gly Asn Ile Arg Gln Ala Thr Val 4725 4730 4735 Lys Trp Ala Met Leu Glu Gln Ile Arg Asn Pro Ser Pro Cys Phe Lys 4740 4745 4750 Glu Val Ile His Lys His Phe Tyr Leu Lys Arg Val Glu Ile Met Ala 4755 4760 4765 Gln Cys Glu Glu Trp Ile Ala Asp Ile Gln Gln Tyr Ser Ser Asp Lys 4770 4775 4780 Arg Val Gly Arg Thr Met Ser His His Ala Ala Ala Leu Lys Arg His 4785 4790 4795 4800 Thr Ala Gln Leu Arg Glu Glu Leu Leu Lys Leu Pro Cys Pro Glu Gly 4805 4810 4815 Leu Asp Pro Asp Thr Asp Asp Ala Pro Glu Val Cys Arg Ala Thr Thr 4820 4825 4830 Gly Ala Glu Glu Thr Leu Met His Asp Gln Val Lys Pro Ser Ser Ser 4835 4840 4845 Lys Glu Leu Pro Ser Asp Phe Gln Leu 4850 4855 <210> 2 <211> 14574 <212> DNA <213> Homo sapiens <400> 2 atggtgactg gtggtggtgc tgcacctccc gggactgtca ctgagccgct tcccagtgtg 60 attgtgctga gcgcaggccg gaagatggcg gctgcggctg cggcggcctc gggccccggc 120 tgctcctcgg cggcgggggc gggggcggcc ggggtctcag agtggctggt gctgcgggac 180 ggctgcatgc actgcgacgc cgacgggctg cacagcctgt cctaccaccc tgcgctcaac 240 gccatcctgg ccgtcactag ccgcgggacc atcaaagtca tcgacggcac ctcgggggcc 300 acactgcagg cctccgcgct cagtgctaaa ccaggtggac aggtgaaatg tcagtatatc 360 tctgctgtgg ataaagttat atttgtggat gattatgcag tagggtgtag gaaggacctt 420 aatggaatct tgttgttaga cactgctctg caaactccag tttcaaagca ggatgatgtg 480 gttcagcttg aattacccgt tacagaggca cagcagctct tatcagcatg tttagaaaag 540 gtagatattt ctagtacaga gggttatgat ttgttcatca cacagctcaa agatggttta 600 aaaaatacat ctcatgagac tgcagcaaac cacaaagttg ctaagtgggc cacagttaca 660 tttcatcttc ctcatcatgt gttgaagtcc attgccagtg ccattgtaaa tgaactcaag 720 aaaataaatc aaaatgttgc tgccttacct gtggcgtcct cagtgatgga cagattgtct 780 tacctcttac ctagtgcacg tccagaactc ggagtggggc caggccgttc tgtagacaga 840 tcactgatgt atagtgaagc taacagacgg gagacattta cctcatggcc tcatgtaggc 900 tataggtggg cacaaccaga tcccatggct caagctggat tttatcatca gcctgcctca 960 tctggagatg atagagccat gtgttttact tgtagtgtat gcctcgtttg ttgggaacct 1020 actgatgaac cttggtctga acacgaaaga cattccccaa actgcccatt tgtgaaaggt 1080 gagcacacac agaatgtgcc attgtcagtc actcttgcaa caagtcctgc acagtttcct 1140 tgtacggatg gaactgacag aatatcttgc tttgggtcgg ggagctgccc tcattttcta 1200 gctgctgcaa ctaaacgagg aaagatctgc atatgggatg tttccaaact tatgaaggtg 1260 cacttaaagt ttgaaattaa tgcctatgat ccagcaattg tacaacagct tattctatca 1320 ggagacccaa gctcaggagt tgattcaagg agaccaactt tggcgtggct ggaggactcc 1380 tctagttgct cagatatacc aaaattggaa ggagatagtg atgatttact ggaggattca 1440 gacagtgaag agcattccag atcagattct gtgacagggc atacatcaca gaaggaagcc 1500 atggaagtaa gccttgatat aacagcactc agcattctcc aacagccaga aaaacttcag 1560 tgggagattg ttgcaaatgt gcttgaagat actgttaagg atcttgaaga acttggggca 1620 aatccttgtt taacaactc tagagtgaa aagacaagg aaagcacca ggcacac 1680 aacattcctt ttccatgttt attagctgga gtttattaa catataaatc tcctgctacc 1740 catcatta gtagtattc cacaggtca ctggatggtt tagcagac tcaggttga 1800 agtatatcag aacaagggtc aactgacaat gatcctgca ctattcaga actaattct 1860 cctctggtaa ggaggacttt accggttttg cttctttata gcatcagga atctgatgag 1920 aaagcaggaa agatctttc acgatgaac atattatga gtaaagtttt gcatgatgat 1980 ggttttactg ttccacagat tattgaatg gagctggata gtcaggagca gttgttattg 2040 caggatcctc ctgtgactta cattcagcaa ttgcagatg cagcagccaa ccttacctct 2100 ccggattctg agaagtggaa ctctgtgttt cccaagcctg ggactttgt tcagtgcttg 2160 aggctgccaa agtttgcaga ggaggagaat ctttgtatag actcaataac tccttgtgct 2220 gacggaatttc atttgttggt aggactgcgg acatgccctg ttgaatcctt gagtgcaata 2280 aatcaagtag aggccttgaa taatttaat aattaact ctgcactatg taatagacgg 2340 aaaggtgagc tggaatcaa tcttgctgta gtgaatggtg caatattag tgtaatccaa 2400 catgaatcac cagcagatgt acagactcct ttaatattc agcctgagca gaggaatgtt 2460 agtggtggat atttagtgct tttaaaatg aattatgcca ctcggatagt gactttagaa 2520 gaggagccaa taaaaataca acatacaa gatccccagg acacattac ctcgctcatt 2580 ttgcttccac ccgatatatt ggataatcga gaggatgact gtgaggaacc tattgaggac 2640 atgcagttaa cctcaaagaa tggtttgag agaaaaaa cgtctgacat ttctactctt 2700 ggacacctgg taataccac tcagggagga tatgtaaaaa tactagatct ttcaacttt 2760 gaaatttgg ccaagtgga gcctccaa aaggaggca ctgaggaca ggacacattt 2820 gtttctgtga tttactgttc tggcacagac aggctgtgtg catgcaccaa aggtggtgag 2880 cttcattttc tccaaattgg aggaacctgt gatgatattg atgaagctga tatactagtg 2940 gatggatctc ttctaaagg atagaacca tctcagaag gttccaacc tttatcaaat 3000 ccttcaagtc ctggcatttc aggagttgat ttattggtgg accagccatt cacccttgaa 3060 atcttgacat ccctagtgga gctaacccgc tttgagactt tgactccaag gttttcagcg actgttcctc catgctgggt together caagaacagc together gcatcctcaa catttgcatc cry tggtgatgct gctcagcata ctcgaacttg gaaactacag accgacagca acagctggga tgaacatgta tttgaattag tactacctaa agcttgtatg gttggacatg tggacttcaa attcgttttg aactcaaaca tcaccaatat tccacagata caagtgacac tgctgaaaaa taaagctcca ggattaggga aagtcaatgc tcttaacatt gagtggac aaaatgggga accgtccctg gttgatttga atgaagaaat gcagcacatg gatgtagagg aatcacagtg tcttagatta tgtccatttt tggaggatca taaagaagac 3540 attctatgtg ggccagtatg gcttgctagt ggccttgatc tatcagggca tgctggaatg 3600 ttgacgttaa caagcccca acttgttaa ggtatggcag gaggaaata tcgttcgttt ttaatccatg tcaaggcagt gaatgaaga ggaacagaag agatttgtaa tggtggtatg cgtcctgtag taaggcttcc atccctaaaa caccagagta acaagggtta ttcacttgct tcacttttgg ctaaagttgc agcaggcaag gaaaaatcat ctaatgttaa gaatgaaaat 3840 acaagtggca cccgtaaatc tgaaaacctc cggggctgtg atttacttca agaggtctca 3900 gtcaccattc gaagatttaa gaaaacctca attctaagg aaagagtgca acgatgtgcc 3960 atgttacagt tttcagaatt tcatgagaag cttcttaata ctctttgcag aaaaacagat 4020 gatggccaga tcacagaaca tgcccagagc cttgtgttgg atactctctg ttggttagct 4080 ggagttcatt caaatggacc cggaagctca aaggaaggaa atgagaacct actttcaaaa 4140 acacgaaaat ttctgtcaga catcgtacgt gtttgcttct ttgaggcagg acgaagtata 4200 gcccataagt gtgccccgatt tctagccttg tgcattagta atggcaaatg tgacccatgt 4260 caaccagcat ttggacctgt tctgttgaag gctttacttg ataatatgtc atttttacct 4320 gcagcaacaa ctggtggttc tgtctattgg tattttgtct tactgaatta tgtgaaagat 4380 gaagatctgg ctggatgcag tacagcttgt gcatctttgc ttactgcagt gtccagacag 4440 ttacaggaca ggctaacacc aatggaggct ttacttcaga caagatatgg attatatagc 4500 tcaccatttg atccagtcct ctttgatttg gagatgagtg gctcttcttg taaaaatgtt 4560 tataacagca gcattggtgt ccagtcagat gaaattgatt tatcagatgt cctttcagga 4620 aatggaaagg tcagtagttg cacagctgct gagggtagtt tcacatctct cactggactt 4680 ttggaagttg aacctctgca ctttacttgt gtgtcaacta gtgatggaac cagaatagaa 4740 agggatgatg caatgagttc cttcggggtt actcctgcag taggtggact atcatctggg 4800 acagttgggg aagcctcgac agccctgagt tcagcagccc aggtagcttt gcagtctctc 4860 tctcatgcaa tggcttcagc cgagcaacag ctacaggtgc tgcaagagaa acagcagcag 4920 cttttgaagc ttcagcaaca gaaagcaaag ctggaagcca agttacatca gacaacagct 4980 gcagcagctg cagcagcatc agcagtaggt cctgttcaca actctgtgcc ttccaaccca 5040 gtggctgccc ctggattctt cattcatcca tctgatgtta ttccacccac tccaaaaaaca 5100 acacctcttt ttatgactcc accactcact ccacccaatg aagcagtttc cgttgtgatt 5160 aatgccgaac ttgcacagct tttcccaggc tcagtcattg atcccccagc agtcaatctt 5220 gctgcacata acaaaaattc caacaagtc agaatgaatc cacttggttc tggtctagcc 5280 cttgcaattt ctcatgcttc acattttctt caacctccgc ctcaccagtc cattattata 5340 gagcgaatgc attcaggagc aagaagattt gtgaccttgg attttgggag gcctatattg 5400 ttgactgatg tattgattcc cacttgtgga gacttggcct cttgtcaat tgacatttgg 5460 acattaggag aagaggtgga tggaaggcgg ttggtagtgg caactgatat aagcactcat 5520 tcactaattc ttcatgactt aataccacct cccgtgtgca gattcatgaa gatcactgtt 5580 attggacgtt acgggagtac aaatgccaga gccaaaatcc cattaggatt ttactatggt 5640 catacctaca tcttgccttg ggaaagtgaa ctgaagttaa tgcatgatcc tctaaaggga 5700 gagggagaat ctgcaaacca gccagaaatt gaccagcatt tagcaatgat ggttgctttg 5760 caggaggata tacagtgcag gtataacttg gcttgtcatc gtctggaaac ccttttgcaa 5820 agtattgatc ttcctcctct aaacagtgct aacaatgcac agtacttttt acgaaaacca 5880 gataaggcag ttgaggaaga cagtagggtt ttttctgctt atcaagattg tattcagcta 5940 cagcttcaac taaatttggc tcataatgca gtgcagaggc tcaaagtggc gctaggtgca 6000 agccggaaga tgttgagtga aacatcaaat ccagaagatt taattcagac atcttccaca 6060 gagcagttac gtactatcat cagatattta ctggacactt tgctcagcct gcttcatgct 6120 tctaatggac actctgttcc tgcagttttg cagagcacat ttcatgccca ggcctgtgaa 6180 gagctcttta aacacttgtg catcagtgga accccaaaga tacggttaca tactggtctt 6240 cttcttgttc aactgtgtgg tggtgaaagg tggtggggtc aatttctttc taatgtcctt 6300 caggaattgt acaattcgga acagcttctc atctttccac aggatagggt cttcatgtta 6360 ctttcctgca ttggtcaaag atcacttagt aatagtggag tattagaaag cttacttaat 6420 ctcttggata atttattgtc acctcttcag ccacagttac ccatgcatag gaggacagaa 6480 ggagtactag atattcccat gatcagttgg gttgttatgc tggtgtccag gttgctggat 6540 tatgtggcaa ctgttgaaga tgaagcagca gctgcaaaga aacctttgaa tggtaatcag 6600 tggagtttta ttaacaataa tctacacact cagagcttaa atagatcttc taaaggcagc 6660 agtagccttg atagattata ttccagaaaa atcagaaagc agctgttca tcataacag 6720 caacttaacc tactaaagc aaagcagaag gcattggtag aacagatgga aaaaaaaaaaaaaaaaaaaaaaaaaaaaa being 6780 atacaagta aaaggatc atcatataaa ctcctggtag aaaaagcaa actaaagcag 6840 gccacttcaa agcactttaa ggatttaatt cgtttacgtc ggacagcaga atggtcccgt 6900 tctaatttag acacagaagt tacacagca aaagaaagtc ctgagataga accacttcca 6960 tttactctgg cccatgagcg ttgtatctca gtagtccaga aacttgttct gttctctctc 7020 tccatggact ttacatgtca tgcagatctc ttattgttg ttgtaggt tcttgcacgc 7080 attgcaaatg ccacgaggcc aactattcat ctgtgtgaga tgtgaacga acccagctg 7140 gaagactgc tgttacttt ggttggaact gactcaata gaggagatat atctttggggt 7200 ggtgcttggg ctcagtattc cttaacttgc atgctacaag atattttagc aggagaatta 7260 ctggctccag tagccgcaga agccatggag gaggacacag tggtgatga tgtaggtgcg 7320 acagctgtg actctgatga ctccttcaa cagtcctcag ttcagttgct ggaaactata 7380 gatgaacctt tgacacatga cataacaggt gcacctcctc tgtcctcttt ggaaaaagat 7440 aaagaaattg accttgagtt acttcaggat ctaatggaag ttgacattga tcctttagat 7500 attgatttgg aaaaggaccc tcttgcagcc aaggttttta agccaataag cagtacatgg 7560 tatgattatt ggggtgctga ttatgggacc tacaattaca acccttacat tggaggtctg 7620 ggaattcctg tagcaaagcc accagcaaac acggagaaga acggatcaca gacagttagc 7680 gtttcagtct ctcaggccct ggatgctcgc ctagaagttg gacttgaaca gcaagcagaa 7740 ctgatgttga aaatgatgtc tactctggag gcagattcca ttttacaggc attaacaaat 7800 acatctccta cattatcaca gtctcccact ggaacagatg attcacttct agggggttta 7860 caagcagcaa accaaaccag ccagcttatt atacagttat catctgtccc aatgttaaat 7920 gtttgtttca acaaactttt ttccatgctt caagtccatc atgttcagtt ggagtcactt 7980 ctccaattgt ggctcacact gagcctgaat tctagttcaa ctggaaacaa agaaaatgga 8040 gcagacatat ttttatataa tgctaatagg atacctgtta tttcattaaa tcaagcatca 8100 ataactagct ttctcacagt gttagcttgg tatcccaata ctttgctccg gacatggtgc 8160 cttgtgcttc atagcctaac actcatgaca aacatgcagc ttaattctgg ttccagcagt 8220 gccattggaa ctcaggagag tactgctcat ttgttggttt cagatccaaa cctaattcat 8280 gtattagtga aatttctttc tggcaccagt ccacatggaa caaatcaaca cagtccacag 8340 gttggtccta cagctacaca agctatgcaa gaatttctta ctcgattaca agtgcatctt 8400 tcttcaacat gtcctcagat attcagtgaa tttttgctca agctaattca tatactttca 8460 actgaaaggg gtgctttcca gacaggccaa ggacctctcg atgcccaagt gaagctctta 8520 gaattcactc tggagcagaa ttttgaagtc gtttcagtta gtactatttc tgccgtgata 8580 gaatcggtta catttttagt gcaccactat atcacttgct cacaaaagt aatgtcaaga 8640 agtggatcag atagctccgt gggtgctcga gcatgctttg ggggactctt tgccaatctt 8700 attcgtccgg gtgatgcaaa agcagtttgt ggcgaaatga caagagatca actcatgttt 8760 gatttgttaa aacttgttaa cattttagtg cagctgcctc tttcaggcaa tagggaatac 8820 agtgcaagag tgtctgtgac cacaaataca acagatagtg tttcagatga agaaaaagtc 8880 tcaggaggca aagatggcaa tggaagcagt accagtgttc aaggatcgcc tgcatatgtt 8940 gctgacttag tcttagccaa ccaacaaatt atgagccaga ttttgtctgc tctgggcctg 9000 tgtaatagca gtgccatggc aatgataatt ggagcaagtg gattacatct cactaaacat 9060 gaaaactttc atggtgggtt ggatgccata tcagttgggg atggattatt taccatactg 9120 acaaccctta gtaaaaaagc ttctacagtc cacatgatgc tgcagccaat tttaacatac 9180 atggcctgtg gatatatggg cagacaagc tctcttgcta cttgccagtt atctgagcca 9240 ttattgtggt tcattttgag agtattggat actagtgatg ccttgaaagc atttcatgat 9300 atgggtggtg ttcagctcat atgcaataat atggttacta gtacaagggc tattgtgaac 9360 actgcaagaa gtatggtatc aactattatg aaatttcttg actctggtcc aaataaagct 9420 gttgacagca cattgaaaac aagaatacta gcttctgagc ctgacaatgc tgaagggatt 9480 cataactttg cacccctcgg tacaatcaca tctagcagtc ctactgccca accagctgaa 9540 <h2 style=";text-align:left;direction:ltr">gtgctattgc aggccacacc tcctcacaga agagctcgct ctgctgcttg gtcctacatc 9600<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> tttcttccag aggaggcttg gtgtgacctt accattcacc ttcctgcagc agtgctgctt 9660<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> aaggagatac atatccagcc tcatcttgca tctcttgcaa cctgcccttc ctcagtgtct 9720<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gttgaagtaa gtgcagatgg ggtaaatatg ctacctttgt ccactcctgt tgtcacaagt 9780<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ggcctcacct acataaaaat tcagcttgta aaagccgaag tagcttctgc tgtctgcctt 9840<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> agactacatc gtccacggga tgccagcaca ttaggccttt cacaaattaa attattgggg 9900<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ctcactgctt ttggtaccac ctcttctgca acagttaata atccattcct tccatctgaa 9960<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gatcaggtat ccaaaacaag tattggatgg ttacggttat tacatcattg ccttactcac 10020<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ataagtgatc tagaaggaat gatggcaagt gcagctgcac ctactgctaa tctgctgcag 10080<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> acttgtgcgg ccttattgat gtcaccttac tgtggaatgc attcacccaa catcgaggtt 10140<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gtgcttgtaa agataggact gcagtctact agaattggcc tgaagctcat agacattctc 10200<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ctgagaaatt gtgcagcatc aggcagtgat cctacagatt tgaatagtcc tttacttttt 10260<h2 style=";text-align:left;direction:ltr"> ggagactaa atggactctc ttctgactct acgatagata ttctttacca gcttggaaca actcaggatc ctggtacaaa agacagaatt caggccttgt taaaatgggt tagtgattct gcaagagtgg ctgctatgaa gagaagtggc aggatgaact acatgtgtcc taactcctca acagtagt atggtcttct gatgccatct ccttctcatt tgcactgtgt agcagccatt ctgtggcata gttatgagct gcttgtagaa tatgacttac cagcactcct ggaccaagag ctctttgagt tactttttaa ttggtccatg tctcttccct gcaatatggt tttgaagaaa gctgttgaca gtctactttg ctcaatgtgt cacgtacacc caaactattt ttctttgctc atgggctgga tgggaattac ccctcctcca gtgcaatgtc atcatagact gtccatgaca price aaaagcagga tcttagttca tctttaacag atgactctaa aaatgcacaa gcacctctcg cattaactga atcacatttg gctacccttg cttcctcttc tcaatctcct 10860 gaagctatta aacaattact agactcaggt ttgccttctc ttcttgtgag gagtctggct agtttctgct ttagccacat ttctagctca gaaagcattg cccagtcaat agatatttcc caggacaaac tcaggcgcca tcatgtccca caacaatgta ataagatgcc tatcacagcc 11040 gacctagttg ctcctattct tagttttg acagaagttg gcaatagcca tattatgaaa 11100 gattggcttg gtggttctga agtcaatcca ctatggacag cacttctgtt tttattgtgt 11160 cactctgggt ccacttctgg aagccataat ttaggtgcac aacagaccag tgcaagatca 11220 gcttctttt cttcagctgc tacaacagga ctgactactc aacagcgcac agcaattgag 11280 aatgcaactg ttgcgttctt tctacagtgc atttcatgcc atcctaataa tcaaaagctg 11340 atggcacagg ttctttgtga actatttcag acatctcctc aaagagggaa ccttccaaca 11400 tctgggaaca tttcagggtt tatacgaaga ttatttac agttgatgct ggaagatgag 11460 aaagtgacaa tgtttcttca gtctccatgt ccactgtaca aaggtagaat taatgctact 11520 agccacgtca tccagcatcc aatgtatgga gcaggccaca aattccgtac tcttcatttg 11580 ccagtctcaa caacattatc agatgttctt gacagagtgt cagatactcc aagtatcaca 11640 gctaaattaa ttagtgaaca aaaagatgac aaagaaaaga aaaaccatga agaaagaa 11700 aaagttaaag cggaaaatgg atttcaagac aattacagtg ttgttgttgc ctctgggctg 11760 aagtctcaat ctaaacgtgc tgtgtcagct acaccacctc gcccaccatc caggaggggg 11820 aggaatac ctgataaaat aggaagtact tcaggagcag aggctgccaa caaataatt 11880 actgtcccag tgtttcacct gtttcacaaa ctcttggcag gccagccatt gccagctgaa 11940 atgacacttg cccagctttt aactctccta tatgaccgaa aacttcctca gggttaccgc 12000 tcaatagatc tgactgttaa attgggatca agagttataa cagaccccag tctatcaaaa 12060 acagattctt ataaaagact acaccctgaa aaagatcatg gagacttact tgctagctgt 12120 ccagaagatg aggctctcac tccaggtgat gaatgcatgg atgggatact ggatgaatct 12180 ttgcttgaaa cctgtccaat tcagtcacca ttacaagttt ttgcaggaat gggtggactg 12240 gctcttattg ctgaaagact acccatgcta tatccagaag taattcaaca ggtgagtgct 12300 ccagttgtaa catctaccac tcaggaaaag ccgaaggata gcgatcagtt tgaatgggtg 12360 accattgaac agtcagggga gttagttat gaagcaccag aaactgttgc ggctgaacct 12420 ccacctatca agtcagcagt acagaccatg tctcccatac ctgcccattc tttggctgct 12480 tttggattat ttcttcgtct tccgggctat gcggaagtgc tactgaaaga gagaaaacat 12540 gcccagtgcc ttcttcgatt ggtattggga gtgacagatg atggagaagg aagtcatatt 12600 cttcaatctc catcagccaa tgtgcttcca acccttcctt tccacgtcct tcgtagcttg 12660 tttagcacta cacctttgac aactgatgat ggtgtacttc taaggcggat ggcattggaa 12720 attggagcct tacacctcat tcttgtctgt ctctctgctt tgagccacca ttccccacga 12780 gttccaaact ctagcgtgaa tcaaactgag ccacaggtgt caagctctca taaccctaca 12840 tcaacagaag aacacagtt atattgggcc aaagggactg gctttggaac aggctctaca 12900 gcttctgggt gggatgtgga acaagcctta actaagcaaa ggctggaaga ggaacatgtt 12960 acctgccttc tgcaggttct tgccagttac ataaatcccg tcagtagtgc ggtaaatgga 13020 gaagctcagt catctcatga gactagaggg cagaacagta atgcccttcc ttctgtactt 13080 ctcgagcttc tcagtcagtc ctgcctcatc ccagccatgt catcttatct acgaaatgat 13140 tcagttctgg acatggcaag acatgtgcca ctctatcggg cactgctgga attgcttcgg 13200 gccattgctt cttgtgctgc catggtgccc ctattgttgc ccctttctac agagaacggt 13260 gaagaggaag aagaacagtc agaatgtcaa acttctgttg gtacattgtt agccaaaatg 13320 aagacctgtg ttgataccta taccaaccgt ttaagatcta aaagggaaaa tgttaaaaca 13380 ggagtaaaac cagatgcgtc tgatcaagaa ccagaaggac ttactctttt ggtaccagac 13440 atccaaaaga ctgctgagat agtttatgca gccaccacca gtttgcggca agcaaatcag 13500 gaaaaaaaac tgggtgaata ctccaagaag gcggctatga aacccaaacc tttgtcagta 13560 ttaaagtcac ttgaagaaaa atatgtggct gttatgaaga aattacagtt tgatacgttt 13620 gaaatggttt ctgaagatga agatgggaaa ttgggattta aagtaaatta ccactacatg 13680 tctcaggtga aaaatgctaa tgatgcgaac agtgctgcca gagctcgccg ccttgcccag 13740 gaagctgtga cgctttcaac ctcactgcct ctgtcttcat cctctagtgt gtttgtacgc 13800 tgtgatgagg agcgacttga tatcatgaag gttctaataa ctggtccagc ggacacccct 13860 tatgcaaatg gctgctttga gtttgatgtg tattttcctc aagattatcc cagttcaccc 13920 cctcttgtga atctagagac aactggtggt catagcgtgc gattcaatcc aaacctttat 13980 aatgatggca aggtttgttt aagcatctta aacacgtggc atggaagacc agaagagaag 14040 tggaatcctc agacctcaag ctttttgcaa gtgttggtgt ctgtccagtc ccttatatta 14100 gtagctgagc cttattttaa tgaaccggga tatgaacggt ctagaggcac tcccagtggc 14160 acacagagtt ctcgagaata tgatggaaac attcgacaag caacagttaa gtgggcaatg 14220 ctagaacaaa tcagaaaccc ttcaccatgt tttaaagagg taatacacaa acatttttac 14280 ttgaaaagag ttgagataat ggcccaatgt gaggagtgga ttgcggatat ccagcagtac 14340 agcagtgata agcgggtagg caggactatg tctcaccatg cagcagctct caagcgtcac 14400 actgctcagc tccgcgaaga gttgctgaaa cttccctgcc ctgaaggctt ggatcctgac 14460 actgacgatg ccccagaggt gtgcagagcc acaacaggtg ctgaggagac tctaatgcat 14520 gatcaggtta aacccagcag cagcaaagaa ctccccagtg acttccagtt atga 14574

Claims

1. Use of an agent for reducing or inhibiting BIRC6 expression in the preparation of a drug for treating triple-negative breast cancer; the agent for reducing or inhibiting BIRC6 expression is selected from the group consisting of gapmer, antisense RNA, siRNA, esiRNA, shRNA, miRNA, RNA aptamer, TALEN, CRISPR and zinc finger nuclease.

2. The use according to claim 1, characterized in that: The nucleotide sequence of the BIRC6 is shown in SEQ ID NO.

2.

3. The use according to claim 1 or 2, characterized in that: The medicament also includes another anticancer agent, which is an agent for reducing or inhibiting the expression of BIRC6 or an agent for inhibiting the binding of BIRC6 to JNK.

4. A method for screening candidate drugs for treating triple-negative breast cancer, characterized in that: The method comprises the following steps: 1) Determine the expression level of BIRC6 in cancer cells that overexpress BIRC6; 2) contacting the candidate compound with the cancer cells identified in step 1); 3) determining the expression level of BIRC6 in the cancer cells obtained in step 2); 4) comparing the expression levels of BIRC6 determined in step 1) and step 3), wherein a decrease in the expression level of BIRC6 indicates that the candidate compound has anti-cancer potential.